Philippines’ hidden health bomb: Obesity costs soar as new cure unveiled

Obesity isn’t just about willpower anymore and it’s already hitting your wallet, your health, and the country’s economy.

That is the message behind Novo Nordisk’s newly launched “Live Lighter” movement in the Philippines, unveiled on April 24, 2026 in Makati City, alongside the introduction of a new prescription obesity drug designed to treat the condition as a chronic disease, not a lifestyle failure.

Novo Nordisk says it is time to rethink how Filipinos see weight gain, shifting from blame to biology. The company introduced a semaglutide-based treatment, a GLP-1 receptor agonist that works by regulating appetite, energy intake, and metabolic processes, targeting the root causes of obesity rather than just the symptoms.

For many people, this hits close to home. Diets that do not work, weight that comes back, and health risks that quietly build up over time are not just personal struggles. According to Dr. Christiana Vida Montefalcon of Novo Nordisk Philippines, obesity often requires long-term medical care, not just exercise and discipline.

The stakes are massive. The EpiCOb-PH study estimates obesity cost the Philippine economy about Php 1.9 trillion in 2025, equivalent to 7.3% of GDP. That figure could climb to Php 2.7 trillion when overweight-related conditions are included. These costs show up in hospital bills, lost productivity, and everyday financial strain.

Beyond the drug, the Live Lighter movement brings together media, healthcare professionals, and patient advocates to push for earlier diagnosis, better treatment access, and less stigma.

Novo Nordisk executives Wei Sun and Anand Shetty say the goal is simple but urgent. Treat obesity as a disease, expand science-based care, and help Filipinos take control of their health in a sustainable way.

Because this is no longer just about weight. It is about how long and how well people live.